Approval · Notice of Compliance 1817 · 1999
CUTIVATE: Notice of Compliance 1817
Issued March 17, 1999
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 1817
- Date
- March 17, 1999
- Company
- Glaxo Wellcome Inc.Mississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Revised dosing schedule
- Therapeutic class
- Anti-inflammatory steroid
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| CUTIVATE | Not yet assigned | — |
Medicinal ingredients
- FLUTICASONE PROPIONATE 0.05 PER